Research and Markets: Outlook of China Drug Formulation - 2011 Market Report

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/a0fd16/outlook_of_china_d) has announced the addition of the "Outlook of China Drug Formulation Market" report to their offering.

It has been well recognized that the drug formulation has been one of the valued-added technologies for both innovative drugs and generics as well as both small molecule drugs and biologics. Although the drug formulation industry has existed in China for decades and growing numbers of Chinese drug companies are currently focusing on this area, their current technical skills and capability are still limited.

However, as the fast growing Chinese pharmaceutical market is providing great opportunities to all types of dosage form drugs, the Chinese drug formulation industry is also currently experiencing significant changes. The growth and development of this Chinese industry have thus started receiving attention of the drug companies from around the world.

The report is a must-read book to all global pharmaceutical and biotechnology companies seeking marketing opportunities in China and collaboration with Chinese drug companies, venture capital investors interested in investment opportunities in the Chinese pharmaceutical industry, market research/consultancy companies seeking the information of the Chinese industry of finished drugs, and even the government agencies of those countries that are interested in learning the current and future development of the Chinese pharmaceutical industry.

Key Findings of the Report

• In the past decade China has been one of the main places in the world for sourcing APIs and pharma intermediates. Almost all world major pharmaceutical, generic drug and specialty pharmaceutical companies have sourced a variety of APIs and pharma intermediates from China. However, even though many Chinese-made APIs not only have low price but also good quality and are thus marketed in the well regulated markets, very few of the formulated forms of these drugs are accepted by these countries.
• In fact, until now China has been weak in drug formulation, which leads to the fact that China has so far not become the main place for those global drug companies to source finished drugs, or partner with Chinese drug companies to manufacture them, or collaborate with the Chinese companies to develop new drug delivery technologies. The main shortcomings associated with this Chinese industry include its low technical capability and lack of familiarity about the product quality regulations in the well regulated markets.
• Currently, there are about 1,400 drug companies in China that are, collectively, able to produce more than 60 dosage forms and about 5,000 different types of medicines. The current Chinese market value of the dosage form medicines is worth about $50 B, accounting for about 5.7% of the global market value. It has grown in 19.3% in a compound annual growth rate (CAGR) in the past five years.
• Internally, aiming to transform the Chinese pharmaceutical industry, the Chinese government is encouraging the Chinese drug companies to upgrade their manufacturing facility and improve their product quality. The SFDA has officially launched the new cGMP standard which has become closer to the Western standards. Meanwhile, growing numbers of Chinese drug companies are also increasing their R&D investment in developing new formulations and devoting their effort to improving their product quality. It is believed that more Chinese companies will soon gain the ability to launch their dosage form products in the well regulated markets.
• It is therefore believed that the Chinese dosage form drug market will continue to grow in a fast pace. It is expected to likely experience a CAGR of about 25% in the next five years. Its market value could reach more than $150 B by 2015. The market value of the Chinese-made dosage form drugs marketed in the overseas market is expected to grow in about 35% a year (CAGR) and could reach around $6.6 B by then.

For more information visit http://www.researchandmarkets.com/research/a0fd16/outlook_of_china_d.